

CERTIFICATE OF MAILING BY FIRST CLASS MAIL (37 CFR 1.8)

Applicant(s): Kevin S. Currie et al.

Docket No.

CGI-0008

Serial No.

10/776,631

Filing Date

February 10, 2004

Examiner

Not Yet Assigned

Group Art Unit

Not Yet Assigned

Invention: Certain 8-Heteroaryl-6-Phenyl-imidazo[1,2-a]pyrazines as Kinase Modulators



I hereby certify that this Trans. of IDS (2 pgs), IDS (2 pgs), PTO-A820 (3 pgs), Cited Art (16 refs), Cert. of mail
(Identify type of correspondence) postcard

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Director of the United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450

on

May 6, 2004


(Date)

Laura J. Nolan

(Typed or Printed Name of Person Mailing Correspondence)

(Signature of Person Mailing Correspondence)

Note: Each paper must have its own certificate of mailing.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kevin S. CURRIE, et al.

Serial No.: 10/776,631

Filed: 02/10/04

For: CERTAIN 8-HETEROARYL-6-PHENYL-
IMIDAZO[1,2-a]PYRAZINES AS
MODULATORS OF HSP90 COMPLEX
ACTIVITY

)
) Group Art Unit: NYA
)
)
) Examiner: NYA
)
)
)
)
)
)
)
)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 AND 1.98

Dear Sir:

In compliance with the duty to disclose, submitted herewith is form PTO-A820 (PTO-1449) listing publication(s) of which those designated by 37 CFR § 1.56 are aware. Copies of the non-United States patents or published applications are enclosed.


The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made, or an admission that the information cited is, or is considered to be, material to patentability.

DE 43 37 609 A1, one of the documents listed on attached Form PTO-1449, is not in English. As required by 37 C.F.R. §1.98(a)(3) applicants have provided below a concise explanation of the relevance of this reference, as well as an Abstract of the PCT counterpart, WO 95/12592. Applicants do not have a translation of this document, but understand it to be directed to pyrazine carboxamide derivatives, for example, those in Table 6 at the top of page 12 and Tables 9 and 9a on pages 14-15. These compounds all have a pyrazine group at the position of W in Formula I of the application and either hydrogen, alkyl, or halogen at the 6-position of the

imidazo[1,2-a]pyrazine core. Compounds disclosed in the application have a substituted phenyl or pyridyl at the 6-position of the imidazo[1,2-a]pyrazine core.

Respectfully submitted,

CANTOR COLBURN LLP

By: 

Leah M. Reimer

Reg. No. 39,341

Date: 5/6/2004
Customer No. 23,413
(860) 286-2929

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
CGI-0008

In Re Application Of: **Kevin S. Currie, et al.**


Serial No.
10/776,631

Filing Date
02/10/2004

Examiner
NYA

Group Art Unit
NYA

Title: **Certain 8-Heteroaryl-6-Phenyl-Imidazo[1,2-a]Pyrazines As Modulators Of HSP90 Complex Activity**



Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
CGI-0008

In Re Application: Kevin S. Currie, et al.


Serial No.
10/776,631

Filing Date
02/10/2004

Examiner
NYA

Group Art Unit
NYA

Certain 8-Heteroaryl-6-Phenyl-Imidazo[1,2-a]Pyrazines As Modulators Of HSP90 Complex Activity



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 06-1130 as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on May 6, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

Laura J. Nolan

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Signature

Dated: May 6, 2004

Leah M. Reimer
Reg. No. 39,341
Customer No. 23,413
(860) 286-2929

CC:

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	Docket Number (Optional) CGI-0008	Application Number 10/776,631
	Applicant(s) Kevin S. Currie, et al.	
	Filing Date 02/10/2004	Group Art Unit NYA



PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5,593,997	01/14/1997	Dow et al.			
		5,658,857	08/19/1997	Andree et al.			
		5,783,576	07/21/1998	Roos et al.			

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
	DE 43 37 609 A1	11.5.95	Germany				✓
	WO 88/04298	16.06.88	International				
	WO 95/12594	11.05.95	International				
	WO 96/04298	15.02.96	International				
	WO 96/34866	07.11.96	International				

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

		Jeffery, Trina K., et al., "Phosphodiesterase III and V Inhibitors on Pulmonary Artery from Pulmonary Hypertensive Rats: Differences Between Early and Established Pulmonary Hypertension" <i>Journal of Cardiovascular Pharmacology</i> 1998, volume 32, no. 2, pages 213-219
		Hanks, Steven K., "Hanks Classification" 1994, Pages 1-4 http://pkr.sdsc.edu/html/pk_catalytic/pk_hanks_class.html

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	ATTY DOCKET NO. CGI-0008	SERIAL NO. 10/776,631
	Kevin S. Currie, et al.	
	FILING February 10, 2004	GROUP NYA

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 99/28322	10.06.99	International				
		WO 01/27119 A2	19.04.2001	International				
		WO 02/30428 A1	18.04.2002	International				
		WO 02/060492 A1	08.08.2002	International				
		WO 02/10170 A1	07.02.2002	International				

OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>			
			Lumma, William C., et al., "Piperazinylimidazo {1,2-a}pyrazines with Selective Affinity for in Vitro ____-Adrenergic Receptor Subtypes" J. Med. Chem. 1983, Volume 26, pages 357-363
			"Protein Kinases in Disease" http://bioinformatics.weizmann.ac.il/Kinases/pkr/pk_medicine.html

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYA

DATE CONSIDERED

PAGE 3 OF 3